Is 2022 the Endemic Year?

Episode Summary

Executive Summary: The episode examines whether Omicron marks a transition from pandemic to endemic COVID-19. Jeffrey Shaman argues Omicron is more transmissible due to faster replication and likely shorter latency, but says its milder severity does not imply future variants will be milder. Eric Topol agrees Omicron is not truly “mild” at scale and warns a more dangerous immune-escape variant could still emerge. Both see vaccines, prior immunity, and Paxlovid as key tools, but say endemicity remains uncertain.

Main Topics: Why Omicron spreads so quickly (Priority: 5/5): Shaman explains Omicron’s higher transmissibility as likely driven by faster replication in human lung tissue, shortened latency, earlier contagiousness, and a larger immune-evasive pool of susceptible people. Why Omicron appears less severe (Priority: 5/5): Omicron seems to favor the upper respiratory tract rather than the lower lungs, reducing the likelihood of severe oxygen-exchange damage and critical illness compared with earlier variants. Whether viruses inevitably evolve to be milder (Priority: 5/5): Shaman rejects the idea that SARS-CoV-2 will naturally become less virulent, arguing that transmission occurs before severe illness and death, so there is little evolutionary pressure for reduced severity. The risk of future immune-escape variants (Priority: 5/5): Both experts caution that Omicron is not necessarily the final major variant; Topol stresses that the next strain could be more dangerous, more immune-evasive, and less predictable than expected. Role of immunity from infection, vaccines, and boosters (Priority: 4/5): Prior infection and vaccination likely reduce severe outcomes even when they do not prevent infection, but protection may not be sterilizing and may be imperfect against future variants. Paxlovid as a game changer (Priority: 5/5): Topol argues Pfizer’s oral antiviral is variant-proof because it targets the virus’s main protease rather than spike, offering a powerful, immune-independent way to reduce viral replication and severe disease. What endemicity could realistically look like (Priority: 4/5): The speakers say an endemic phase may emerge, but likely not as a simple once-a-year flu-like pattern; outbreaks could remain recurrent, disruptive, and dependent on future variant evolution.

Key Arguments: Omicron’s rapid spread is likely tied to shorter latency and faster viral replication, allowing it to infect people before Delta can. Omicron’s reduced severity appears linked to upper-respiratory replication rather than deep lung involvement, but that does not guarantee future variants will be milder. Evolutionary theory does not reliably predict a gentler SARS-CoV-2 because transmission happens before severe symptoms or death, limiting pressure for lower virulence. The next variant may emerge from a different branch of the phylogenetic tree, not necessarily from Omicron’s lineage, so assuming a gradual path toward harmlessness is risky. Topol argues Omicron is only “mild” in a relative sense; because infections are so numerous, total severe cases can still be high. Vaccines remain highly valuable against hospitalization and death, especially with boosters, but they are not fully protective against infection or future immune escape. Paxlovid is highlighted as especially important because it works independently of antibodies and targets a conserved viral protease, making it likely to remain effective across variants. Endemicity may mean recurring, manageable waves rather than the disappearance of COVID-19; the burden depends on frequency, severity, and the rise of new variants.

Data Points: Pandemic duration referenced: about two years - The discussion is framed around SARS-CoV-2’s evolution over the first two years of the pandemic. Variant replacement speed: Delta went from dominant to completely Omicron-dominated over the course of December - Used to illustrate Omicron’s extreme transmissibility and competitive advantage. Global deaths from COVID-19: maybe 20 million - Shaman uses this estimate to argue the virus has not depleted the pool of susceptible hosts. World population: 7.7 billion - Context for why the virus still has a vast population to infect. Vaccine effectiveness after two doses against hospitalization: about 50% - Topol notes two-dose protection against Omicron hospitalization remained meaningful but limited. Vaccine effectiveness after a third shot against hospitalization: 90% or greater - Topol cites strong booster protection despite immune evasion. Original vaccine development timeline: 10 months - Topol contrasts mRNA vaccine speed with the typical decade-long development process. Typical vaccine development timeline: 10 years - Used to emphasize the extraordinary speed of COVID vaccine development. Pfizer antiviral trial efficacy: about 90% prevention of hospitalization and death - Topol describes Paxlovid’s trial results as unprecedented. U.S. vaccination rate mentioned: 62% - Topol uses this to argue that the country is unlikely to reach the hoped-for 90% vaccination threshold. Ideal vaccination threshold mentioned: 90% - Topol says this level would have been needed to move more confidently toward endemicity.

Pivotal Quotes: "the way it becomes milder is because of the exposure we've had and the exposure is had because of infection naturally and vaccination." — Jeffrey Shaman: On why reduced severity is more plausibly due to immunity buildup than to viral evolution toward harmlessness. "I have to respect this virus more than ever in terms of where it can go." — Eric Topol: On the continued unpredictability of SARS-CoV-2 and the risk of a future worse variant. "I call it a just-in-time breakthrough." — Eric Topol: On Paxlovid’s significance as a variant-independent treatment arriving during Omicron’s immune escape.

Implications: COVID may become more manageable, but not predictably mild or seasonal. Future risk depends on variant evolution, vaccination/booster coverage, and deployment of variant-proof treatments like Paxlovid.